What is Dolby Laboratories, Inc.'s business segments — R&D?

Dolby Laboratories, Inc. (DLB) reported business segments — R&D of $53.84M in Q1 2026.

How has Dolby Laboratories, Inc.'s business segments — R&D changed year-over-year?

Dolby Laboratories, Inc.'s business segments — R&D increased by 2.2% year-over-year, from $52.66M to $53.84M.

What does business segments — R&D mean?

Captures the costs incurred to develop new technologies, improve existing products, or innovate within the segment's specific market. High investment here is typically essential for maintaining a competitive advantage in technology-driven industries.

Dolby Laboratories, Inc. (DLB) Business Segments — R&D

Screener

Similar metrics at other companies

MANEReportable Segment — R&D

$17.19M+85.3%

ZSReportable Segment — R&D

$143.5M+35.4%

SNOWReportable Segment — R&D

$534.94M+13.2%

VEEVReportable Segment — R&D

$156.76M+15.2%

BCAXReportable Segment — R&D

$47.5M+38.4%

SLABReportable Segment — R&D

$88.59M+0.4%

Other financials

Income statement

See full

Revenue$395.6M+7.1%

Gross profit$350.9M+5.1%

Operating income$112.9M+4.8%

Net income$94.9M+3.4%

EPS (diluted)$0.99+5.3%

Balance sheet

See full

Cash & equivalents$673.8M-10.2%

Total debt$49.7M+22.9%

Total equity$2.6B+1.7%

Total assets$3.2B+0.6%

Cash flow

See full

Operating cash flow$92.5M-47.1%

CapEx$9.1M+31.4%

Free cash flow$83.4M-50.3%

Valuation

See full

Market cap$5.71B-17.7%

Enterprise value$5.08B-18.2%

P/E23.4×-2.8×

P/S4.2×-1.0×

Profitability

See full

Gross margin87.4%-1.5pp

Operating margin18.5%-2.0pp

Net margin17.9%-1.6pp

FCF margin22.1%-7.5pp

Returns & leverage

See full

Return on equity9.4%-0.9pp

Debt / equity0×0.0×

Current ratio3×-0.1×

Where this comes from

Reported directly by Dolby Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Dolby Laboratories, Inc.’s 10-Q, filed April 30, 2026.

Filed: Apr 30, 2026, 4:45 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q1 2026
Accession: 0001308547-26-000010

Line item	Fiscal Quarter Ended / March 27, 2026	Fiscal Quarter Ended / March 28, 2025	Fiscal Year-To-Date Ended / March 27, 2026	Fiscal Year-To-Date Ended / March 28, 2025
Less:
Cost of licensing (1)	17,454	12,965	31,626	27,371
Cost of products and services (1) (2)	19,492	15,010	40,640	33,353
Research and development expense (1) (2)	53,844	52,664	111,353	108,318
Sales and marketing expense (1) (2)	85,591	78,672	164,085	159,672
General and administrative expense (1) (2)	64,139	57,976	120,259	114,242
Restructuring charges	2,184	4,210	12,650	9,426
Stock-based compensation	30,708	30,664	67,919	66,734

ITEM 1. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Dolby Laboratories, Inc.'s business segments — R&D?: Dolby Laboratories, Inc. (DLB) reported business segments — R&D of $53.84M in Q1 2026.
How has Dolby Laboratories, Inc.'s business segments — R&D changed year-over-year?: Dolby Laboratories, Inc.'s business segments — R&D increased by 2.2% year-over-year, from $52.66M to $53.84M.
What does business segments — R&D mean?: Captures the costs incurred to develop new technologies, improve existing products, or innovate within the segment's specific market. High investment here is typically essential for maintaining a competitive advantage in technology-driven industries.

Ask your AI about Dolby Laboratories, Inc.'s business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Dolby Laboratories, Inc. DLB Business Segments — R&D

Similar metrics at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Dolby Laboratories, Inc.'s business segments — r&d.